Literature DB >> 2579826

In vitro characterization of the alpha-adrenoceptors in human prostate.

J P Hieble, M Caine, E Zalaznik.   

Abstract

The alpha-adrenoceptors of the human prostate gland were characterized in vitro by the use of antagonists selective for alpha 1- and alpha 2-adrenoceptor subtypes. The contractile response induced by norepinephrine in this tissue could be antagonized by prazosin, a selective alpha 1-antagonist, with a receptor dissociation constant (KB) of 4.0 +/- 0.9 nM. The selective alpha 2-antagonists rauwolscine and SK&F 86466 were less potent antagonists of this response, with KB values of 1020 +/- 400 nM and 2400 +/- 800 nM, respectively. The irreversible alpha-antagonists benextramine and phenoxybenzamine, both of which preferentially inactivate the alpha 1-subtype, produced marked depression of norepinephrine-induced contraction. These data would suggest that the alpha-receptors on prostatic smooth muscle are predominantly of the alpha 1-subtype.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579826     DOI: 10.1016/0014-2999(85)90048-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  22 in total

1.  The effects of SB 216469, an antagonist which discriminates between the alpha 1A-adrenoceptor and the human prostatic alpha 1-adrenoceptor.

Authors:  R Chess-Williams; C R Chapple; F Verfurth; A J Noble; C J Couldwell; M C Michel
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  Identification of alpha 1-adrenoceptor subtypes in the dog prostate.

Authors:  T Ohmura; S Sakamoto; H Hayashi; S Kigoshi; I Muramatsu
Journal:  Urol Res       Date:  1993-05

Review 3.  Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

Review 4.  Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; D McTavish
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

5.  Characterization of alpha 1-adrenoceptor subtypes in tension response of human prostate to electrical field stimulation.

Authors:  J H Guh; S C Chueh; F N Ko; C M Teng
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

6.  Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract.

Authors:  F Lefèvre-Borg; S E O'Connor; H Schoemaker; P E Hicks; J Lechaire; E Gautier; F Pierre; C Pimoule; P Manoury; S Z Langer
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

7.  Alpha 1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Evidence for heterogeneity of chloroethylclonidine-resistant rat renal alpha 1-adrenoceptor.

Authors:  M C Michel; R Büscher; J Kerker; H Kraneis; W Erdbrügger; O E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-10       Impact factor: 3.000

8.  Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype.

Authors:  I Marshall; R P Burt; C R Chapple
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

9.  Noradrenergic vasoconstriction of pig prostatic small arteries.

Authors:  Paz Recio; Luis M Orensanz; María Pilar Martínez; Jorge Navarro-Dorado; Salvador Bustamante; Albino García-Sacristán; Dolores Prieto; Medardo Hernández
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

10.  A1 and A2A adenosine receptor modulation of alpha 1-adrenoceptor-mediated contractility in human cultured prostatic stromal cells.

Authors:  A Preston; M Frydenberg; J M Haynes
Journal:  Br J Pharmacol       Date:  2004-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.